Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Urol. Jul 24, 2014; 3(2): 139-143
Published online Jul 24, 2014. doi: 10.5410/wjcu.v3.i2.139
Published online Jul 24, 2014. doi: 10.5410/wjcu.v3.i2.139
Table 1 Clinicopathologic characteristics of castration-resistant prostate cancer patients n (%)
| Variable | Value |
| Patients, n | 33 |
| Median (range) | |
| Age at start of chemotherapy, years | 71.5 ± 7.4 (55-83) |
| PSA levels at start of chemotherapy, ng/mL | 93.3 ± 131.3 (6.3-744.5) |
| PSA levels (initial diagnosis), ng/mL | 877.8 ± 2259.1 (21.0-12490) |
| Dose of docetaxel, mg/body | 88.1 ± 24.7 (40-130) |
| Dose of docetaxel, mg/m2 | 53.3 ± 13.1 (30-70) |
| Number of cycles, n | 11 ± 8.5 (1-33) |
| Survival period after chemotherapy, mo | 16.2 ± 12.0 (0.2-38.6) |
| Clinical T stage | |
| 3 | 28 (84.8) |
| 4 | 5 (15.2) |
| Lymph node status | |
| 0 | 15 (45.5) |
| 1 | 18 (54.5) |
| Gleason sum (initial diagnosis) | |
| < 6 | 3 (10.0) |
| 7 | 7 (23.3) |
| 8 | 5 (16.7) |
| 9 | 11 (36.7) |
| 10 | 4 (13.3) |
| EOD score (initial diagnosis) | |
| 0 | 12 (36.4) |
| 1 | 3 (9.1) |
| 2 | 10 (30.3) |
| 3 | 8 (24.2) |
- Citation: Endo T, Kamiya N, Suzuki H, Oka R, Lee FC, Utsumi T, Yano M, Kamijima S, Kawamura K, Imamoto T, Ichikawa T. Bone markers predict survival in castration-resistant prostate cancer patients treated with docetaxel. World J Clin Urol 2014; 3(2): 139-143
- URL: https://www.wjgnet.com/2219-2816/full/v3/i2/139.htm
- DOI: https://dx.doi.org/10.5410/wjcu.v3.i2.139